Surrozen (SRZN) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Surrozen (SRZN) has outperformed Zura Bio (ZURA) over the past year, gaining 115.7% versus a loss of 3.6%. Zura Bio is the larger company by market cap ($383.3 million vs $349.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRZN | ZURA |
|---|---|---|
| Share price | $29.69 | $4.00 |
| Market cap | $348.96M | $383.32M |
| 1-day change | +6.15% | -3.15% |
| YTD return | +31.37% | -23.66% |
| 1-year return | +115.68% | -3.61% |
| 5-year return | -68.68% | — |
| EPS (TTM) | $-39.08 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.83 | $7.44 |
| 52-week low | $11.39 | $3.15 |
| Distance from 52-week high | -21.52% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.02% | +350.00% |
| Average volume | 493.16K | 1.44M |
| Shares outstanding | 11.75M | 95.83M |
| Employees | 44 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed ZURA by 119.3 percentage points over the past year.
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
SRZN vs ZURA FAQ
Which is bigger, Surrozen or Zura Bio?
Zura Bio (ZURA) is larger, with a market capitalization of $383.32M compared with $348.96M for Surrozen (SRZN).
Which stock has performed better over the past year, SRZN or ZURA?
SRZN returned +115.68% over the past 12 months, compared with -3.61% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Surrozen and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.